Orion Corporation upgrades the full-year outlook estimate for 2011 provided in the Financial Statement Release 2010 and published on 9 February 2011. The company estimates that well-developed sales in early 2011 will also reflect on the development of full-year operating profit.
New full-year outlook estimate for 2011, provided on 13 April 2011
Net sales will be slightly higher than in 2010.
Marketing expenditure will be higher due to the increased number of product launches. Research expenditure will be higher than in 2010.
Operating profit excluding non-recurring items will be higher than in 2010.
The Group's capital expenditure will be about EUR 45 million excluding substantial corporate or product acquisitions.
Previous full-year outlook for 2011, provided in Financial Statement Release 2010
Net sales will be slightly higher than in 2010.
Marketing expenditure will be slightly higher due to the increased number of product launches. Research expenditure will be clearly higher than in 2010.
Operating profit excluding non-recurring items will be slightly higher than in 2010.
The Group's capital expenditure will be about EUR 45 million excluding substantial corporate or product acquisitions.
Orion will publish the Interim Report January-March 2011 on Wednesday, 27 April 2011.
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to approximately EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.